Table 4.
Cerebrospinal fluid (CSF) findings in patients with COVID-19 and different neurological conditions
| Clinical manifestation | N° patients | Proteins (mg/dL) | Cells (cells/μL) | SARS-CoV-2 PCR | ||||
|---|---|---|---|---|---|---|---|---|
| Average | Range | Average | Range | Positive | Negative | N/M | ||
| Cerebrospinal fluid findings in patients with central nervous system involvement by SARS-CoV-2 | ||||||||
| Encephalopathy | 13 | 67·3 | 0 to 230 | 9·8 | 0 to 37 | 0 | 9 | 4 |
| Encephalitis | 7 | 83·1 | 19 to 200 | 40.6 | 0 to 115 | 2 | 5 | 0 |
| Demyelinating lesions in brain and spine | 4 | 47 | 32 to 62 | 1 | 1 | 1 | 1 | 2 |
| Meningoencephalitis | 3 | 463·5 | 461 to 466 | 17.3 | 0 to 21 | 1 | 2 | 0 |
| Stroke | 3 | 50 | 50 | 0 | 0 | 0 | 2 | 1 |
| Seizures | 3 | 66 | 66 | 3 | 1 to 5 | 0 | 3 | 0 |
| Brain vasculopathies | 2 | 292·5 | 78 to 507 | 6.5 | 0 to 13 | 0 | 2 | 0 |
| Rhombencephalitis | 1 | 42·3 | 42.3 | 0 | 0 | 0 | 0 | 1 |
| Maniac episode | 1 | 190 | 190 | 0 | 0 | 0 | 1 | 0 |
| Total | 37 | 4 | 25 | 8 | ||||
| Cerebrospinal fluid findings in patients with peripheral nervous system involvement by SARS-CoV-2 | ||||||||
| Guillain-Barré syndrome | 17 | 105·9 | 40 to 193 | 2.4 | 0 to 9 | 0 | 11 | 6 |
| Miller-Fisher syndrome | 2 | 75 | 62 to 80 | 2.5 | 0 to 5 | 0 | 1 | 1 |
| Polineuritis cranealis | 1 | 62 | 62 | 2 | 2 | 0 | 1 | 0 |
| Facial palsy | 2 | 44 | 44 | 0 | 0 | 0 | 2 | 0 |
| Total | 22 | 0 | 15 | 7 | ||||